Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
about
Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?Diagnosis and therapy of non-variceal upper gastrointestinal bleedingExtending the translational potential of targeting NO/cGMP-regulated pathways in the CVSThe David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environmentAdherence to guidelines for avoiding drug interactions associated with warfarin--a Nationwide Swedish Register StudySafe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksCOX-2 inhibition: what we learned--a controversial update on safety data.A review of the gastrointestinal safety data--a gastroenterologist's perspective.Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.Patient benefit-risk in arthritis--a rheumatologist's perspective.Effect of a Proton Pump Inhibitor on Tumor Bleeding Prevention in Unresectable Gastric Cancer Patients: a Double-Blind, Randomized, Placebo-Controlled TrialPrevention of chronic NSAID induced upper gastrointestinal toxicity.Recent advances in peptic ulcer bleeding.Consensus on control of risky nonvariceal upper gastrointestinal bleeding in Taiwan with National Health Insurance.Topical NSAID therapy for musculoskeletal pain.Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidanceAdherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey.Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity.The Indications, Applications, and Risks of Proton Pump InhibitorsImpact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study.Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain.Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review.Superior digestive tract side effects after prolonged treatment with NSAIDs in patients with osteoarthritis.Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study.Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries.Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.Management of chronic nonmalignant pain with nonsteroidal antiinflammatory drugs. Joint opinion statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy.Treatment and chemoprevention of NSAID-associated gastrointestinal complications.Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage.Celecoxib in arthritis: relative risk management profile and implications for patients.Treatment options for osteoarthritis: considerations for older adults.Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Update on the endoscopic management of peptic ulcer bleeding.Expert panel consensus recommendations for the pharmacological treatment of acute pain in the Middle East region.Management of patients with ulcer bleeding.Coming to terms with nonsteroidal anti-inflammatory drug gastropathy.Therapeutic management of recurrent peptic ulcer disease.
P2860
Q22306448-50273F00-F818-4F36-9C75-3B1D87B46CEFQ26777626-32FD6B08-02A6-4DE5-AAF8-3E46ADD4B844Q27021649-4DFEA206-9552-464A-93C6-463EEE800B7DQ28222253-18194E7D-4351-435B-AA5A-4D31C18BF896Q28538870-C49BDD7E-B2A3-40F5-A1EE-A80BC5A0B146Q30629677-96DDA34A-4758-4545-A441-E2564AE58529Q30724476-43A790E5-F6D6-45A2-8D20-E3192E86D676Q33560647-86C4C03D-72C6-40D0-96E1-D601B9A2B913Q33698340-4D85AD56-90BC-4FB4-AC11-40AD4FAEC529Q33803037-AC99D87C-774C-482A-865A-89752A376DEBQ33849286-05BBD8DF-8B0A-401D-A8B0-45370BA1216CQ33978682-CAF9DF25-0467-421E-93DC-672DE96842ACQ34076408-DEA3467D-B92A-4F00-ADCA-AFF8B57CA196Q34100357-B8D20D39-0F51-48FC-ABCF-DE3787B7369AQ34617511-2F9CA60E-E6D0-4722-81D7-C4B2943FF0E1Q34655792-B046E8CB-8FE0-445B-8B70-E7A270223D77Q35949108-FEB866F9-891C-48C2-9AD3-A889D1F6CA2EQ36001198-2851BFCA-9C57-489B-9F1A-64C169BD2EE7Q36091187-611B33BD-25EA-4629-98EB-B23D3DF9AC94Q36174087-FC3E47CE-21D8-4836-B740-885B13B18F0DQ36235082-90B2AC2A-7868-43F8-9BCE-15B18302E2BDQ36246550-8919864D-E450-463F-A6F4-8FEB284B2A90Q36309948-C130766F-2F67-4012-B111-1D56D3BF901BQ36332697-7AAC8ECB-C235-4F68-B00E-39ECFFAFC915Q36844540-72933424-698C-47F6-9008-EE5DA4896B89Q36904910-C35BF833-ECEB-4552-872D-8D53206A9DE8Q37173212-402070B3-B5A2-4318-B6BC-91463BCFAA39Q37230285-4D0CB259-2AB4-4FFF-909C-7A4B80768DF6Q37272199-AAA20EEB-5C15-4833-A8E0-39C894BC1074Q37358250-2BAF9E52-B732-4072-912C-0DD61FCDC389Q37475646-1B17636C-7136-42E9-8590-F0617BF0E7F5Q37476761-6E187FB2-7B5A-4296-B602-299005112A9DQ37643458-1B12357B-ADC0-4113-ABE7-EA6356CB8AE4Q37858371-EBE3F0F5-E0AD-4BB9-8041-1814C1A711D6Q37893966-C89C2645-46A7-47CA-8602-95CD86275F7EQ37932430-101E5507-74CC-4CBC-B031-B824B965C36DQ37943977-C952C1B1-8CFB-428C-8CBC-2D0F6EE446D7Q37981830-D3035084-BC29-44A7-ABD7-10FC8CA04945Q38008020-7CAB40BF-B1E3-4EE0-B060-A237F0748013Q38032319-007D9E8D-2628-492F-B218-F91D6B731F33
P2860
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Combination of a cyclo-oxygena ...... ouble-blind, randomised trial.
@en
type
label
Combination of a cyclo-oxygena ...... ouble-blind, randomised trial.
@en
prefLabel
Combination of a cyclo-oxygena ...... ouble-blind, randomised trial.
@en
P2093
P50
P1433
P1476
Combination of a cyclo-oxygena ...... double-blind, randomised trial
@en
P2093
Aric Josun Hui
Bing Yee Suen
Dorothy Kai Lai Chow
Francis Ka Leung Chan
Grace Lai Hung Wong
Henry Lik Yuen Chan
James Yun Wong Lau
Jessica Yuet Ling Ching
Justin Che Yuen Wu
P304
P356
10.1016/S0140-6736(07)60749-1
P407
P577
2007-05-01T00:00:00Z